JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

Home・Akcijų sąrašas・Eli Lilly and Co.

Eli Lilly and Co.

Uždarymo kaina

SektoriusSveikatos priežiūra

1,007.5 -0.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

995

Max

1015.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	758M 7.4B
Pardavimai	507M 20B
P/E Sektoriaus vid.	34.327 51.415
Pelnas, tenkantis vienai akcijai	8.55
Dividendų pajamingumas	0.66
Pelno marža	37.355
Darbuotojai	50,000
EBITDA	971M 9.4B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+24.33% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.66% 2.34%
Kitas uždarbis	2026-08-05
Kitas dividendų mokėjimo data	2026-06-10
Kita Ex Dividend data	2026-05-15

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	87B 862B
Ankstesnė atidarymo kaina	1008.29
Ankstesnė uždarymo kaina	1007.5

Naujienos nuotaikos

By Acuity

33%

67%

93 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

N/A / 884.54 Palaikymas ir pasipriešinimas

Eli Lilly and Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 12:01; UTC

Uždarbis

Pagrindinės rinkos jėgos

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

2026-05-07 09:30; UTC

Uždarbis

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

2026-05-06 12:36; UTC

Uždarbis

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

2026-05-06 10:12; UTC

Uždarbis

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

2026-05-06 09:58; UTC

Uždarbis

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

2026-04-30 20:59; UTC

Karštos akcijos

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

2026-04-30 20:12; UTC

Uždarbis

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026-04-30 16:43; UTC

Uždarbis

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

2026-04-30 16:10; UTC

Rinkos pokalbiai

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

2026-04-30 15:13; UTC

Uždarbis

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026-04-30 14:58; UTC

Uždarbis

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

2026-04-30 14:53; UTC

Uždarbis

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

2026-04-30 14:50; UTC

Uždarbis

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

2026-04-30 14:42; UTC

Uždarbis

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

2026-04-30 14:39; UTC

Uždarbis

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

2026-04-30 14:35; UTC

Uždarbis

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

2026-04-30 14:24; UTC

Uždarbis

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

2026-04-30 14:17; UTC

Uždarbis

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

2026-04-30 13:56; UTC

Uždarbis

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026-04-30 13:37; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

2026-04-30 12:32; UTC

Rinkos pokalbiai

Uždarbis

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

2026-04-30 12:29; UTC

Rinkos pokalbiai

Uždarbis

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

2026-04-30 12:23; UTC

Rinkos pokalbiai

Uždarbis

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

2026-04-30 12:10; UTC

Uždarbis

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026-04-30 12:08; UTC

Uždarbis

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

2026-04-30 12:04; UTC

Rinkos pokalbiai

Uždarbis

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

2026-04-30 11:39; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

2026-04-30 11:08; UTC

Uždarbis

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026-04-30 10:50; UTC

Uždarbis

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

2026-04-30 10:49; UTC

Uždarbis

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Akcijų palyginimas

Kainos pokytis

Eli Lilly and Co. Prognozė

Kainos tikslas

By TipRanks

24.33% į viršų

12 mėnesių prognozė

Vidutinis 1,262.85 USD 24.33%

Aukščiausias 1,500 USD

Žemiausias 850 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Eli Lilly and Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

22 ratings

Pirkti

Laikyti

Parduoti

Remiantis 22 analitikų, pateikusių Eli Lilly and Co. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 884.54Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

93 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.